Why Tempus AI is perfectly positioned to squeeze Wall Street out of their own position.

If you own **$TEM** and can't figure out why it keeps selling off while the company puts up numbers, I'm going to explain exactly what's happening.

This isn't about fundamentals. This is about market plumbing. And most of you have never heard of the trade that's crushing this stock.

On May 8th Tempus priced a convertible notes offering.

Started at $350M, got upsized to $400M, then the initial purchasers exercised their full greenshoe and it ballooned to 460M.

Zero coupon. Matures 2032. Converts at $69.26 per share which was a 40% premium to the stock at the time.

The deal closed May 12th. And that's when things got ugly.

These notes didn't get bought by long only funds or pension managers.

They got scooped up by convertible arb desks.

And here's what those desks do the second they buy a convert:

They short the stock.

Every single time. It's not a choice. It's the strategy. That's convertible arbitrage.

Let me explain why because this is the part nobody teaches retail.

A convertible note is a bond with an embedded call option. The arb desk doesn't want the equity exposure from that option. They want the credit spread and the vol premium.

So they calculate the delta of the embedded option and short that many shares against it. Now they're flat on direction. The stock can go up or down and they don't care. They're collecting carry on a market neutral position.

This is literally textbook stuff on every trading floor in Manhattan.

Now do the math on the selling pressure.

$460M in notes at a $69.26 conversion price means roughly 6.6 million shares worth of conversion exposure.

The delta on a 40% out of the money convert is probably 0.3 to 0.5.

On a mid cap stock with average daily volume around 7 million shares, that is a massive wave of concentrated selling.

Which is exactly why we see so much added short pressure on Tempus as of recently.

The short interest data tells you exactly when it happened.

As of May 15th (three days after the deal closed): 35.17 million shares short.

That's a 31% increase from the prior period. 35.5% of the entire public float is now sold short. Days to cover ratio: 4.9.

Over a third of every tradeable share is borrowed and sold. And the spike lines up perfectly with the convert closing date.



But here's where it gets painful for retail.

You open your brokerage app. You see short interest through the roof. You see the stock dropping. Every instinct says "people are betting against this company."

Wrong.

Nobody on those arb desks has an opinion on Tempus. They didn't read the 10K. They don't know what MRD testing is. They bought a bond and hedged the delta. That's it. There's no thesis. There's no bear case. It's a mechanical trade.

Then the reflexivity kicks in.

Arb desks short the stock. Price drops. Retail sees the drop and the short interest spike and panics. They sell. Price drops more. More retail sees the chart breaking down and dumps. Short interest as a percentage of float keeps climbing because the float's market cap is shrinking.

It feeds on itself. But the whole thing started with a capital markets transaction, not a fundamental deterioration. The business didn't change. The float dynamics did.

Meanwhile, what did Tempus actually do with the $460M?

They took $307.7M and paid off every dollar of their senior secured credit facility. That was real interest bearing debt held by Ares Capital. It's gone.

They replaced it with zero coupon notes. Literally 0.00% interest. They swapped expensive debt for free money that doesn't come due for six years.

They also spent $31.2M on capped call transactions. The cap is at $98.94 per share. That means there's no dilution from conversion unless the stock goes above $99. Below that, shareholders are fully protected.

The rest sits on the balance sheet.

I need you to sit with that for a second.

The company eliminated its entire senior credit facility. Replaced it with zero interest debt. Protected shareholders from dilution up to $99. Freed up cash flow that was going to interest payments. Extended maturity to 2032.

That's a textbook smart capital structure move. The CFO did their job. And the stock got punished because of how the buy side hedges converts.

The business got stronger. The stock went down. Those two facts can coexist and they do all the time in markets. But for how long?

And the fundamentals? They're not just fine. They're accelerating.

Q1 2026 revenue: $348M, up 36% year over year.

Diagnostics doing $261M a quarter.

Data licensing grew 44%.

MRD testing volume up 500% year over year.

Full year guidance raised to 1.6B.

Targeting $65M in adjusted EBITDA, which would be their first full year of positive adjusted profitability

BMS expanded. Merck expanded. Daiichi Sankyo signed on. They just held their first ever Investor Day.

Nothing about this business says sell.

So how does this unwind? Let's talk gamma trading.

Convertible arb hedges are dynamic. The funds rebalance constantly. If the stock goes down, the bond's delta drops. To stay market neutral, the arb desks actually have to BUY shares back to cover part of their short.

They literally become forced buyers on the way down. This is what eventually puts a mechanical floor on the stock.

But what happens if the stock rips on good news?

This is where it gets explosive. If the stock moons, the arb desks are supposed to short more shares to stay hedged. But if borrow costs spike, or if the float is already choked out, the plumbing breaks.

They get margin called. They get squeezed on their short side before the convert can compensate. They are forced to cover. That's a short squeeze.

So picture this:

A catalyst hits and retail buys the dip, locking up the float. As the stock rips, math dictates arb desks must short MORE shares to stay hedged.

But the borrow is gone. Prime brokers issue margin calls. Funds are forced to abandon their hedge and buy shares at market price from the very retail investors holding the line.

That parabolic forced buying into a zero supply market is how retail traps Wall Street in their own mechanical game.

Tempus has no shortage of catalysts to trigger exactly that scenario.

Just last week on May 29th, they got FDA approval for a tumor only indication on their xT CDx panel. They no longer need a matched normal sample like blood or saliva to run the test.

This means they can migrate their entire solid tumor portfolio to an FDA approved assay.

Why does that FDA label matter?

Because FDA approved companion diagnostics get reimbursed by insurance at a massive premium over lab developed tests. We're talking hundreds of dollars of pure margin upside per test starting in 2027.

That is millions in free cash flow dropping straight to the bottom line just from a regulatory update.

Then you have upcoming earnings in mid August.

Remember their guidance: $65M in adjusted EBITDA for the full year. They printed negative in Q1. That means Q2, Q3, and Q4 have to show a massive inflection in profitability to hit that target.

If they print a big beat in August and prove the profitability story is real, that 35% short interest becomes pure jet fuel.

The setup is almost perfectly asymmetrical.

You have a multi billion dollar healthcare AI platform executing flawlessly. It's trading at a massive discount entirely because of mechanical hedge fund selling. It's sitting on a 35% short float. And it's going into a major inflection quarter with new FDA approvals in hand.

If you're holding $TEM and watching the tape wondering what went wrong, nothing went wrong. You're watching the plumbing work. This happens with mid cap convert deals and retail gets shaken out of great positions because of it every single time.